|Day Low/High||93.27 / 97.03|
|52 Wk Low/High||89.76 / 285.00|
Clovis Oncology, Intercept Pharmaceuticals and Editas Medicine were among the biotech premarket movers on July 31.
Ocaliva represents the first new treatment option in over 20 years for PBC, an autoimmune liver disease that is the leading reason for liver transplantation in women in Canada
Paratek Pharmaceuticals, Immunomedics and Intercept Pharmaceuticals were among the biotech stock movers in premarket trading Tuesday.
In highlights from this week's trading diary and posts, Kass offers some advice about fundamentals and about what earnings season means.
Intercept says it received approval from the FDA.
Intercept claims FDA approved the OCA study modifications, but like most pharma companies, no proof was offered, just verbal assurances.
The companies inked a $250 million deal on Friday that could be worth up to $2 billion, thanks to milestone payments.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.